Technology ID
E-175-2009-0

Conditional V2 Vasopressin Receptor Mutant Mice as a Model to Study X-linked Nephrogenic Diabetes Insipidus (XNDI)

Linked ID
TAB-2078
Inventors
Chung-Lin Chou (NHLBI)
Chuxia Deng (NIDDK)
Jianhua Li (NIDDK)
Jurgen Wess (NIDDK)
Mark Knepper (NHLBI)
Stasia Anderson (NHLBI)
Lead Inventors
Jianhua Li (NIDDK)
Co-Inventors
Chung-Lin Chou (NHLBI)
Chuxia Deng (NIDDK)
Jurgen Wess (NIDDK)
Mark Knepper (NHLBI)
Stasia Anderson (NHLBI)
Applications
Research Materials
ICs
NIDDK
NHLBI
X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss of renal urine-concentrating ability. At present, no specific pharmacological therapy has been developed for XNDI, primarily due to the lack of suitable animal models. This technology provides a unique and viable animal model of XNDI. NIH investigators have generated mice in which the V2R gene could be conditionally deleted during adulthood by administration of 4-OH-tamoxifen. Radioligand-binding studies confirmed the lack of V2R-binding sites in kidneys following 4-OH-tamoxifen treatment, and further analysis indicated that upon V2R deletion, adult mice displayed all characteristic symptoms of XNDI, including polyuria, polydipsia, and resistance to the antidiuretic actions of vasopressin.

Gene expression analysis suggested that activation of renal EP4 PGE2 receptors might compensate for the lack of renal V2R activity in XNDI mice. Strikingly, both acute and chronic treatment of the mutant mice with a selective EP4 receptor agonist greatly reduced all major manifestations of XNDI, including changes in renal morphology. These physiological improvements were most likely due to a direct action on EP4 receptors expressed on collecting duct cells. These findings illustrate the usefulness of V2R mutant mice for elucidating and testing new strategies for the potential treatment of humans with XNDI.

Request More Info

Licensing Contact